Welcome to our dedicated page for Beyondspring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
BeyondSpring Inc. director and Chief Executive Officer Huang Lan received a grant of stock options to acquire 11,514 Ordinary Shares. The options have an exercise price of $1.804 per share and were awarded at no cost to the reporting person.
According to the grant terms, 2,878 options will vest on each of April 1, 2027, April 1, 2028 and April 1, 2029, and 2,880 options will vest on April 1, 2030, subject to continuous service with the company. The options expire on April 1, 2031. This is a compensation-related award rather than an open-market purchase or sale.
Xu Sihai reported acquisition or exercise transactions in this Form 4 filing.
BeyondSpring Inc. director Xu Sihai received a grant of stock options covering 18,689 ordinary shares. The options have a strike price of $1.64 per share and expire on April 1, 2036.
According to the grant terms, all of these stock options vest on April 1, 2027, provided Xu continues to serve with the company through that date. This award increases his directly held derivative position to 18,689 options and reflects compensation rather than an open-market purchase or sale.
BeyondSpring Inc. reports another year of operating losses as it advances its oncology pipeline. The company generated no revenue in 2025 and recorded a consolidated net loss of $14.2 million, narrowing from $16.7 million in 2024, with losses driven by research and development and general and administrative expenses.
Cash and cash equivalents from continuing operations were $7.8 million as of December 31, 2025, while net cash used in operating activities increased to $19.8 million. The balance sheet shows total assets of $25.9 million against total liabilities of $49.9 million, resulting in a shareholders’ deficit of $24.0 million.
BeyondSpring continues to focus on Plinabulin, a first-in-class small molecule for non-small cell lung cancer and other cancers, supported by positive Phase 3 data (DUBLIN-3) and multiple investigator-initiated trials. It also retains an equity stake in SEED Therapeutics, which is advancing a targeted protein degradation platform and has initiated a Phase 1 study of its RBM39 degrader.
Management states it expects ongoing losses and indicates that additional capital—through equity, debt, partnerships, or asset sales—will be required to fund development and operating needs, with potential dilution and other financing constraints highlighted as key risks.
BeyondSpring Inc. reports another year of operating losses as it advances its oncology pipeline. The company generated no revenue in 2025 and recorded a consolidated net loss of $14.2 million, narrowing from $16.7 million in 2024, with losses driven by research and development and general and administrative expenses.
Cash and cash equivalents from continuing operations were $7.8 million as of December 31, 2025, while net cash used in operating activities increased to $19.8 million. The balance sheet shows total assets of $25.9 million against total liabilities of $49.9 million, resulting in a shareholders’ deficit of $24.0 million.
BeyondSpring continues to focus on Plinabulin, a first-in-class small molecule for non-small cell lung cancer and other cancers, supported by positive Phase 3 data (DUBLIN-3) and multiple investigator-initiated trials. It also retains an equity stake in SEED Therapeutics, which is advancing a targeted protein degradation platform and has initiated a Phase 1 study of its RBM39 degrader.
Management states it expects ongoing losses and indicates that additional capital—through equity, debt, partnerships, or asset sales—will be required to fund development and operating needs, with potential dilution and other financing constraints highlighted as key risks.
BeyondSpring Inc. reported full-year 2025 results and highlighted major clinical milestones for its lead cancer drug Plinabulin and equity affiliate SEED Therapeutics. For continuing operations, research and development expenses rose to $4.4 million from $2.6 million, while general and administrative expenses decreased to $4.6 million from $6.1 million. Net loss from continuing operations was $8.7 million, similar to $8.9 million in 2024, and cash, cash equivalents and short-term investments totaled $12.6 million as of December 31, 2025. Including discontinued operations related to SEED, net loss was $14.2 million, but net loss attributable to BeyondSpring narrowed sharply to $1.0 million, with basic and diluted loss per share improving to $0.02 from $0.28. Clinically, Phase 3 DUBLIN-3 data in EGFR wild-type NSCLC showed a statistically significant overall survival benefit for Plinabulin plus docetaxel versus docetaxel alone, with a hazard ratio of 0.72 and a 2.5-month median overall survival improvement, and supported plans for the global Phase 3 DUBLIN-4 confirmatory trial. Early combination studies suggested Plinabulin may help overcome resistance to PD-1/PD-L1 therapies. SEED advanced its RBM39 degrader ST‑01156 into Phase 1a trials, secured U.S. Orphan Drug and Rare Pediatric Disease designations, and completed a $30 million Series A‑3 financing.
BeyondSpring Inc. reported full-year 2025 results and highlighted major clinical milestones for its lead cancer drug Plinabulin and equity affiliate SEED Therapeutics. For continuing operations, research and development expenses rose to $4.4 million from $2.6 million, while general and administrative expenses decreased to $4.6 million from $6.1 million. Net loss from continuing operations was $8.7 million, similar to $8.9 million in 2024, and cash, cash equivalents and short-term investments totaled $12.6 million as of December 31, 2025. Including discontinued operations related to SEED, net loss was $14.2 million, but net loss attributable to BeyondSpring narrowed sharply to $1.0 million, with basic and diluted loss per share improving to $0.02 from $0.28. Clinically, Phase 3 DUBLIN-3 data in EGFR wild-type NSCLC showed a statistically significant overall survival benefit for Plinabulin plus docetaxel versus docetaxel alone, with a hazard ratio of 0.72 and a 2.5-month median overall survival improvement, and supported plans for the global Phase 3 DUBLIN-4 confirmatory trial. Early combination studies suggested Plinabulin may help overcome resistance to PD-1/PD-L1 therapies. SEED advanced its RBM39 degrader ST‑01156 into Phase 1a trials, secured U.S. Orphan Drug and Rare Pediatric Disease designations, and completed a $30 million Series A‑3 financing.
BeyondSpring Inc. major shareholders Lan Huang and Linqing Jia have jointly reported beneficial ownership of 6,048,488 ordinary shares, equal to 15% of the company’s outstanding stock. The filing aggregates shares held through British Virgin Islands entities, personal holdings, grantor retained annuity trusts, a charitable foundation, and irrevocable trusts for Dr. Huang’s children.
The percentage is calculated against 40,322,320 ordinary shares outstanding as of September 30, 2025, as disclosed in BeyondSpring’s Form 10-Q. Huang and Jia report shared voting power over all 6,048,488 shares and shared dispositive power over 1,231,804 of those shares.
BeyondSpring Inc. received an amended Schedule 13G from Decheng Capital-affiliated funds and Dr. Xiangmin Cui reporting their passive ownership of the company’s ordinary shares. The filing reflects positions as of December 31, 2025.
The group reports beneficial ownership of 3,800,702 ordinary shares by Dr. Cui, representing 9.2% of the outstanding class, held through Decheng Capital China Life Sciences USD Fund II, Fund III and Decheng Capital Global Healthcare Fund. The percentage is based on 41,122,320 ordinary shares outstanding as of November 18, 2025. The signatories certify the shares are not held for the purpose of changing or influencing control of BeyondSpring.
BeyondSpring Inc. reports an expected delay in completing the “Second Closings” of its sale of Series A-1 Preferred Shares of SEED Therapeutics Inc. under previously signed purchase agreements.
The company had agreed to sell an aggregate 8,333,637 SEED Series A-1 Preferred Shares for approximately $35.4 million, or $4.25 per share. As part of this, Winning View Investment Limited, FULL TECH CORPORATE DEVELOPMENT LIMITED and Mapfil Investment Limited are scheduled to buy 1,436,327, 555,576 and 1,111,152 shares, respectively, in the Second Closings.
These Second Closings were originally to occur no later than December 15, 2025, but are now expected to be completed in the first half of 2026, with no assurance against further delays or certainty on the exact timing.
BeyondSpring Inc. entered into a Securities Purchase Agreement with Ray Beauty Group Limited for a registered offering of 800,000 ordinary shares at $2.50 per share. The transaction closed on November 21, 2025, providing gross proceeds of $2.0 million before expenses. The shares were issued off an effective shelf registration statement on Form S-3. The investor agreed to a 60-day lock-up from closing, limiting sales and derivative transactions in the shares without the company’s prior written consent, subject to specified exceptions.
BeyondSpring Inc. (BYSI) is conducting a primary offering of 800,000 ordinary shares to Ray Beauty Group Limited at $2.50 per share, raising an estimated $2 million in net proceeds after expenses. The company plans to use the cash to fund its research and development programs and for general corporate purposes, which may include clinical trial and commercial spending, working capital, debt repayment and potential acquisitions.
Shares outstanding are expected to increase from 40,322,320 to 41,122,320 as of the referenced date, modestly diluting existing holders. As of September 30, 2025, BeyondSpring reported a net tangible book value of $(0.49) per share, which would improve to $(0.43) per share on an as-adjusted basis after the offering, but investors buying in this deal face an immediate dilution of $2.93 per share. The company remains a clinical-stage biopharmaceutical developer centered on its lead oncology asset, Plinabulin, and additional preclinical immune agents.
BeyondSpring Inc. filed its Q3 2025 10‑Q, showing a year‑to‑date swing to positive net income attributable to the company of $1,131, driven by a $6,986 gain on sale of subsidiary interests tied to its SEED Therapeutics divestiture plan. From continuing operations, the company reported a year‑to‑date operating loss of $6,349 as it had no revenue, with research and development at $2,915 and general and administrative at $3,434.
Cash and cash equivalents were $12,483 at September 30, 2025. Net cash used in operating activities was $14,265 year‑to‑date, offset by $15,934 provided by investing activities, including proceeds from maturities of short‑term investments and the SEED transaction. Total assets were $29,484, total liabilities $49,294, and shareholders’ deficit widened to $(19,810), reflecting high deferred revenue balances and noncontrolling interests.
The SEED plan advanced: the first closing on February 19, 2025 sold 1,730,454 Series A‑1 shares for $7,354. A second closing is scheduled no later than December 15, 2025, and a third by December 15, 2026, which would reduce BYSI’s SEED stake to 13.62% upon completion. Shares outstanding were 40,332,320 as of September 30, 2025.